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A B S T R A C T
Chitosan is a nature-based polymer with low toxicity, excellent biocompatibility and biodegradability. However,
the intractable solubility of chitosan in water and most conventional solvents hampers its biomedical applica-
tions. Following the dissolution method for dissolving chitosan in plain water developed by us, chitosan was
dissolved in ionic liquid followed by overnight freezing at −20 °C and subsequent solvent exchange with plain
water at room temperature. In this study, we fabricated a drug-carrying chitosan film via solution casting and
air-drying by using the plain water-based chitosan solution. Specifically, brimonidine tartrate (BT), an anti-
glaucoma drug, was dissolved in the plain-water based solution and used to prepare BT-loaded chitosan film, i.e.,
chitosan-BT film. The resulting film is transparent, structurally stable, and mucoadhesive. Micro-sized anti-
glaucoma BT drug crystals form and are well dispersed in the chitosan film. The chitosan-BT film enables BT to
have a high corneal permeability with fast drug release kinetics for potential ocular drug delivery.
1. Introduction
Chitosan is a nature-based polymer commonly obtained from the
deacetylation of chitin, one of the most abundant and renewable bio-
polymers on the earth after cellulose. Due to good biocompatibility and
biodegradability, chitosan has broad applications in the fields of cos-
metic, food, pharmaceutical and biomedicine [1–10]. Food and Drug
Administration (FDA) has approved chitosan-based wound dressings
[11]. Inheriting biologically desired characteristics such as anti-bac-
teria and bioadhesion, chitosan films have been used as food wraps,
artificial skins, contact lenses and so on [12–15]. However, the poor
solubility of chitosan is still an issue for fabrication. It is difficult to
dissolve chitosan into water and most solvents because of the inter-
molecular and intramolecular hydrogen-bonded network [16].
Acids like acetic acid are commonly used to dissolve chitosan [17].
However, the use of acids may involve many corrosive processes and
the acid residues may affect the skin, mucosa, tissue and so on. Alkali
neutralization and water washing usually follow the acid treatment to
remove acids from chitosan. Nevertheless, the residues of acids and
alkalis may remain in products and have adverse biological effects. In
addition, it remains a challenge to incorporate water-soluble com-
pounds into chitosan during the solubilization process. Recently, ionic
liquids (ILs) have received much attention as solvents for chitosan so-
lubilization because of their compelling features, such as non-volatile,
high thermal and chemical stability, and easy to recycle [18]. ILs are
more environmentally friendly and the chitosan/ILs systems have better
processability to develop chitosan materials [18]. Although previous
studies showed that some ionic liquids are relatively safe for industrial
applications, the toxicity of ionic liquids still needs to be further elu-
cidated to support the biological use of chitosan/ILs systems [19,20].
Plain water can be the safest and the most applicable solvent to develop
chitosan-based biomedical materials. In our previous study, we devel-
oped an ecofriendly method for dissolving chitosan in plain water [21].
In the method, chitosan was first dissolved in the ionic liquid EMIM Ac
and then the chitosan/ionic liquid mixture was kept at −20 °C over-
night. Then, the extensive solvent exchange with plain water at room
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temperature was conducted to obtain a stable dispersion of nanosized
chitosan in plain water. In the process, the hydrogen-bonded network of
chitosan is disrupted by the ionic liquid to free the amines that parti-
cipate in hydrogen bonding. The intermediate freezing step prevents
the dissolved chitosan from reconnecting with hydrogen-bonding in-
teractions. The solvent-exchange step leads to the protonation of chit-
osan's amine groups, which in turn promotes chitosan solvation in plain
water. This method eliminates solvent effects and skips tedious post-
solubilization processes. Furthermore, it opens up opportunities to de-
velop and apply chitosan-based products for those biomedical appli-
cations that depend critically on safer formulations such as ocular drug
delivery.
In this work, we developed an ocular drug-loaded chitosan film by
using the plain water-based chitosan solution. Drug-carrying film ma-
terials such as therapeutic contact lenses have been applied to treat eye
diseases recently [22–26]. Brimonidine tartrate (BT) is an antiglaucoma
drug commonly taken in the form of eye drops. The efficacy of BT can
be improved in many aspects through the use of polymer carriers
[27–31]. In our new formulation, micro-sized brimonidine tartrate
crystals formed within the chitosan film through the solution casting
and air-drying process. The SEM, swelling, stability and light trans-
mittance experiments were conducted to characterize the chitosan film.
The cytotoxicity and mucoadhesion for the obtained film were also
investigated. The drug release kinetics and permeability of BT in the
form of the chitosan-BT film were studied. With excellent biocompat-
ibility and high corneal permeability of the drug, this drug-carried
chitosan film can be potentially used for ocular drug delivery.
2. Materials and methods
2.1. Materials
Chitosan with high molecular weight (HMW)
(310,000–375,000 Da), ionic liquid 1-ethyl-3-methylimidazolium
acetate (EMIM Ac, ≥95.0%) and cell proliferation reagent WST-1 were
purchased from Sigma-Aldrich (St. Louis, MO). Brimonidine tartrate
(BT) (salt form) was purchased from AvaChem Scientific (San Antonio,
TX). Water (HPLC grade), acetonitrile (ACN, HPLC grade), tri-
fluoroacetic acid (TFA), phosphate-buffered saline (PBS, 10 × ), ELISA
kits of human IL-6, IL-β and TNF-α were purchased from Thermo Fisher
Scientific (Logan, UT). Gastric porcine mucin was purchased from
PFALTZ&BAUER, Inc. (CT, USA). The concentration of mucin was
measure by Pierce™ BCA protein assay kit purchased from Thermo
Fisher. Fresh rabbit whole eyes were purchased from Pel-Freeze
Biologicals (Rogers, AR). Rhodamine B (RB) was purchased from Fluka.
2.2. Methods
Preparation of Chitosan Films. The plain water-based chitosan solu-
tion was prepared following our previous method [21]. Briefly, the
HMW chitosan was dissolved in ionic liquid EMIM Ac and frozen
overnight, then solvent exchanged with plain water to form the plain
water-based chitosan solution with a concentration of about 2.4 mg/mL
[21]. Chitosan film was prepared by casting 2 mL of the plain water-
based chitosan solution into a rounded polytetrafluoroethylene (PTFE)
mold with a diameter of 32 mm followed by air-drying overnight.
Brimonidine tartrate (BT) was dissolved in the plain water-based chit-
osan solution with a concentration of 1 mg/mL. Following the same
casting-drying method, chitosan-BT film was prepared. Rose-colored
chitosan-RB film was also prepared. The obtained films were punched
by a 6 mm-diameter puncher for further use (Fig. 1).
Scanning Electron Microscopy (SEM). Chitosan film and chitosan-BT
films (before and after drug release) were sputter-coated with platinum
for 90 s. Then, SEM images were taken on a scanning electron micro-
scope (Hitachi FE-SEM Su-70, Japan).
Swelling Studies. The swelling behavior of the chitosan film was
determined by immersing chitosan film in PBS (pH 7.4, 1 × ) at 37 °C.
The swollen chitosan film was gently taken out and weighted at dif-
ferent time intervals. The measurement duration was up to 24 h in
order to reach the maximum absorption. The swelling ratio was cal-
culated by: Swelling ratio (%) = (Wt - W0)/W0 × 100, where Wt re-
presents the mass of the swollen sample at time point t and W0 re-
presents the initial mass of the sample.
Stability Studies. The stability of chitosan film was investigated by
monitoring the mass of the chitosan film after swelling equilibrium in
PBS (pH 7.4, 1 × ) at 37 °C. The chitosan film was immersed in PBS (pH
7.4, 1 × ) at 37 °C and the mass of the swollen chitosan film at 24 h was
taken as the initial mass (ms). The mass of the swollen sample at time
point t is defined as mt. The ratio of mt/ms represents the weight change
and the stability of the chitosan film.
Light Transmittance. The visible light transmittance of the chitosan
film was measured with a UV–Vis spectrophotometer (Evolution 201) in
the wavelength range from 400 to 800 nm.
Cytotoxicity Assessment. Cytotoxicity of the chitosan film was eval-
uated on both NIH3T3 mouse embryo fibroblasts cells and primary
human corneal epithelial (HCE) cells. HCE cells, derived from normal
human corneal tissue, were cultured following the manufacturer's in-
structions in complete corneal epithelial cell growth medium. HCE cells
within third passages were used. Chitosan film was sterilized by UV
irradiation before use. NIHT3T3 cells were seeded in a 6-well plate at a
density of 5 × 105 cells/well. HCE cells were seeded in a 12-well plate
at a density of 5 × 104 cells/well. The cells were cultured for 24 h to
allow attachment. Sterilized chitosan film was put in an insert with
different doses. The inserts loaded with chitosan films were placed in
the wells, immersed by cell culture medium without contacting with the
cells. After 24-h culture, the cytotoxicity was analyzed by WST-1 assay.
For quantification of cytokines, 600 μL of the culture media of HCE cells
was collected and centrifuged after 6-h culturing. The supernatants
were subjected to ELISA analysis following the manufacturer's in-
structions.
Mucoadhesion Tests. To assess mucoadhesive properties of the chit-
osan film, a series of mucin aqueous solutions were prepared for
quantitative analysis of the interaction between mucin particles and the
chitosan film [32]. A standard curve was created by using Pierce™ BCA
protein assay kit following the manufacture's procedure with different
mucin concentrations (2000, 1500, 1000, 500, 200, 100, and 20 μg/
mL). Chitosan film (~1.43 mg, ~2.30 cm2) was added to 1 mL of as
prepared mucin solution (2 mg/mL). After determined time points (1 h,
2 h, and 24 h), the concentration of the mucin solution was analyzed
using the same assay kit as the standard curve. The mucoadhesive
property of the chitosan film was calculated by (m0-mt)/s, where m0 is
the mass of mucin in the solution before chitosan film adsorption, mt is
the mass of mucin in the solution after chitosan film adsorption, s is the
adsorption area of the chitosan film. The adsorption area of 1.43 mg
chitosan film is about 4.60 cm2.
In Vitro Drug Release Kinetics. Drug release from chitosan-BT film
was performed. Briefly, 0.8 mg of chitosan-BT film containing about
222 μg of BT was immersed in 1 mL of PBS in a centrifuge tube. The
tube was maintained at 37 °C. At predetermined time intervals, 1 mL of
PBS medium was withdrawn, and 1 mL of fresh PBS was added to
maintain a constant volume. The BT concentration in the withdrawn
PBS medium was analyzed on HPLC based on a standard curve of BT.
All experiments were performed in triplicate.
Ex Vivo Permeation Studies. The corneal permeability of BT in the
chitosan-BT film was evaluated in a Franz diffusion cell system
(PermeGear, Hellertown, PA) [33]. The Franz diffusion cell had a dif-
fusion area of 0.785 cm2 with a donor chamber and a receiver chamber.
Cornea wasextracted from fresh rabbit eye and immediately mounted in
the diffusion cell with the epithelial surface facing the donor chamber
and the endothelial surface facing the acceptor chamber. A rounded
chitosan-BT film with a 6 mm diameter attached to the cornea epithelial
surface and loaded in the donor chamber with 200 μL of PBS. The
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receiver chamber of the diffusion cell was filled with 5 mL of PBS. At
predetermined time points up to 1 h, an aliquot of 500 μL PBS was
withdrawn from the receiver chamber and analyzed by HPLC, and fresh
PBS (500 μL) was added to the receiver chamber after each sampling.
All the experiments were conducted in triplicate. The permeability
coefficient, P, was calculated as follows: P = (dQ/dt)/AC, where dQ/dt
is the steady-state slope of a cumulative flux curve, C is the loading
concentration of BT in the donor chamber, and A is the effective cross-
sectional area (0.785 cm2) for diffusion. Flux (μg/cm2/h) is determined
by (dQ/dt)/A [33].
Statistical Analysis. The data were reported as means ± standard
deviation (SD). Student's t-test was conducted for statistical analysis. P
values less than 0.05 were considered statistically significant.
3. Results and discussion
The chitosan film and chitosan-BT film were prepared through a
solution casting and air-drying process with plain water as the solvent
(Fig. 1). Fig. 2 shows the SEM images of the chitosan film and chitosan-
BT film before and after drug release. As shown in Fig. 2a and b, a
smooth chitosan film was obtained after evaporating the solvent of
plain water at room temperature. The thickness of the chitosan film is
about 3.5 μm. After dissolving of brimonidine tartrate (BT) in the plain
water-based chitosan solution, a chitosan-BT film was prepared. BT
crystals are uniformly formed and well dispersed in the chitosan film, as
shown in Fig. 2c. Submicron/micro-sized BT particles (Fig. 2c inset) are
loaded on the surface and inserted into the inside of the chitosan film
(Fig. 2d). After drug release from the chitosan-BT film, micro-sized BT
crystals disappear from the smooth chitosan film (Fig. 2e and f).
As shown in Fig. 3, the swelling ratio of the chitosan film reaches to
1987% at 6 min and exceeds 2000% within 15 min. Then, the swelling
ratio fluctuates around 2300% for a swelling equilibrium. The high
swelling capacity of the chitosan film in PBS is attributed to the ex-
tremely hydrophilic nature and the high affinity to the salt solutions of
chitosan due to the hydroxy and amino groups [34,35]. In this study, a
chitosan film formed following solution casting and air-drying of the
plain water-based chitosan solution. During the chitosan solution pre-
paration, the hydrogen-bonded network of chitosan was disrupted, and
Fig. 1. Preparation of chitosan film and chitosan-BT film.
Fig. 2. SEM images of chitosan film (a, b), chitosan-BT film (c, d), and chitosan-BT film after drug release (e, f).
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the chitosan system experienced a significant volume expansion during
solvation [21]. Upon drying, the hydrogen-bonded network restores
and the chitosan film forms, in which chitosan molecules are connected
via a relatively extended chain conformation, leading to increased ex-
posure of hydrophilic functional groups (hydroxy and amino groups).
This is presumably attributed to the unusually high swelling ratio for
the film prepared using our method compared with chitosan film pre-
pared using the traditional method [36]. The chitosan film has a high
swelling ratio in PBS, an attribute enabling drug carrier to efficiently
release drug to the aqueous environment via swelling-controlled dif-
fusion.
The stability of the chitosan film is shown in Fig. 4. Good stability
has been found for the chitosan film with no obvious change of the
weight ratio over 35 days. By using an ecofriendly method in our pre-
vious study, a plain water-based chitosan solution was prepared
through breaking the hydrogen-bonded network of chitosan and the
chitosan amino groups are protonated by water molecules [21]. As the
removal of plain water by air-dying, the hydrogen-bonded interactions
among chitosan macromolecules restore, and a stable chitosan film
forms with the recovered hydrogen-bonded network. The obtained
chitosan film is stable and insoluble in PBS. It is possible to develop this
chitosan film as a stable drug-carrier such as ocular insert.
Fig. 5 shows the transmittance spectrum and photograph of the
chitosan film. The chitosan film is flexible and transparent (Fig. 5,
inset). Good light transmittance was exhibited by the chitosan film with
a light transmittance value of over 70% from 400 nm to 800 nm. Many
transparent film materials as functional contact lenses showed im-
proved effects for eye treatment [15,22–26]. As a transparent film, this
chitosan material can be potentially composed of a contact lens for
ocular drug release.
The compatibility of the chitosan film was studied by cytotoxicity
assessments on both NIH3T3 cells and HCE cells, as shown in Fig. 6. The
cytotoxicity was not observed on NIH3T3 cells when the concentration
of chitosan film is up to 1050 μg/mL (Fig. 6a). When the concentration
of chitosan film is lower than 808 μg/mL, the chitosan film is also cy-
tocompatible on HCE cells, as shown in Fig. 6b. IL-6, IL-β, and TNF-α
cytokines on the HCE cells were analyzed following treatment with
chitosan film at 269, 403, and 808 μg/mL. The chitosan film does not
accelerate the secretion of IL-β and TNF-α. No IL-β and TNF-α signals
were detected in the experiments. Chitosan film at concentrations of
403 and 808 μg/mL partly decreases the IL-6 levels on HCE cells
(Fig. 6c). Generally, the cytotoxicity of the chitosan film was not ob-
served according to the viability assessments of NIH3T3 cells and HCE
cells. Chitosan is considered to be a biomaterial with very low toxicity
[37]. Avoiding the solvent effects, chitosan products can practically
meet the need of bioapplication. The chitosan film prepared from the
solvent of plain water shows excellent compatibility for biomedical
uses.
The mucoadhesive properties of the chitosan film were tested by its
interactions with mucin [32]. When adding a polymer film into a mucin
solution, the concentration of the mucin would decrease if the polymer
film has the affinity to the mucin. As shown in Fig. 7, the concentration
of the mucin solution drops from 2000 μg/mL to ~1500 μg/mL at 1 h,
and to ~1400 μg/mL over 2 h. The absorption of mucin particles on
chitosan film (~1.43 mg) accounts for the decrease of the mucin con-
centration, which indicates the mucoadhesive properties of the chitosan
film. The mucoadhesive property of the chitosan film to mucin is about
128 μg/cm2. The mucoadhesive property of the chitosan to mucin is
attributed to their many interactions, such as hydrogen bonding, elec-
trostatic interactions, hydrophobic effects and so on [38]. The mu-
coadhesive chitosan film has a great potential for transmucosal ad-
ministration.
In vitro drug release kinetics of BT for the chitosan-BT film in PBS at
37 °C are shown in Fig. 8. BT is released quickly from the chitosan-BT
film. More than 75% of the drug is released within 6 min, and about
90% of drug is released less than half an hour. The remaining BT drug
shows a relatively slow release. The chitosan film is extremely hydro-
philic, and water solution can be easily absorbed by the chitosan film as
Fig. 3. Swelling behavior of chitosan film in PBS at 37 °C.
Fig. 4. Stability of chitosan film in PBS at 37 °C.
Fig. 5. Transmittance spectrum of the chitosan film. Inset: chitosan film shows
excellent optical transparency.
B. Li, et al. Bioactive Materials 5 (2020) 577–583
580
shown from the results of the swelling behavior (Fig. 3). With a large
surface area, micro-sized BT drug would fast dissolve in the aqueous
environment. According to the results of drug release (Fig. 8) and SEM
(Fig. 2), the fast release is from the fast-dissolved BT particles loaded on
the surface of the chitosan-BT film, and the relatively slow release is
attributed to the remaining drug inserted into the inside of the chitosan-
BT film.
As a model to show the practical release to the eye globe, a rho-
damine B (RB)-loaded chitosan film (chitosan-RB film) has been pre-
pared using the same method as the chitosan-BT film. The chitosan-RB
film and the rabbit eye globe are chosen to demonstrate the release
behavior as shown in Fig. 9. A rose-colored chitosan film was obtained
(Fig. 9a). As shown in Fig. 9b, the chitosan-RB film on the rabbit eye
globe shows good mucoadhesion. The mucoadhesive property of the
chitosan film is further supported by the mucin experiments (Fig. 7).
The chitosan-RB film almost turns transparent after release, and RB is
well released onto the rabbit globe as shown in Fig. 9c. The light
transmission of the chitosan film (Fig. 5) would maintain after the re-
lease of RB. It is consistent with the fast release behavior of chitosan-BT
film with about 75% BT drug having been released in 6 min as shown in
Fig. 8.
The transport of BT across the rabbit cornea was further studied
with the chitosan-BT film. As shown in Fig. 10, the cumulative flux
curve of BT displays a linear increase within the first 30 min and
reaches a plateau afterward. The permeability is then calculated ac-
cording to the linear range (Fig. 10 inset) of the cumulative flux curves.
The cornea permeability of BT in the chitosan-BT film is determined to
be 1.62 × 10−5 cm/s, which is much higher than the permeation
coefficient from many previous systems [28,30]. Typical permeability
coefficient for brimonidine range is between 2.1 × 10−7 and
3.6 × 10−7 cm/s [28,39]. Nano/micro-sized drug preparations can
improve drug solubility and bioavailability due to the large surface area
[40,41]. The micro-sized BT preparation through the chitosan film
(Fig. 2) can significantly improve the BT transport across the cornea for
ocular release. Although the release of BT is fast, this chitosan-BT film
could possibly be an alternative of eye drops since the released BT can
efficiently cross the cornea.
4. Conclusion
In this work, a chitosan film loaded with micro-sized drug was
prepared using a simple and ecofriendly method based on solution
casting and air-drying of plain water-based chitosan solution.
Brimonidine tartrate (BT) as a model drug was incorporated to form a
chitosan-BT film. Micro-sized BT crystals uniformly form and are dis-
persed in the chitosan film. The chitosan film is transparent and stable
with good properties of mucoadhesion and biocompatibility. BT is re-
leased fast from the chitosan-BT film but has a high cornea perme-
ability. This chitosan-BT film has a great potential to be used for ocular
drug delivery.
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